


Docket No. 217323US0PCT/hc



1627
RECEIVED
NOV 15 2002
TECH CENTER 1600/2900
#8/100
11-2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mitsuhiro NAKAMURA, et al.

SERIAL NO: 09/926,818

GAU: 1627

FILED: December 21, 2001

EXAMINER:

FOR: METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references, some of which are cited in the attached Taiwanese Office Action listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon


Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 03/02)

Roland E. Martin
Registration No. 48,082

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

217323US0PCT

SERIAL NO.

09/926,818

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Mitsuhiro NAKAMURA, et al.

FILING DATE

December 21, 2001

GROUP

1627

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
8	AO	10-14596	01/20/98	JAPAN (with English translation)	X	
8	AP	WO 99/10526	03/04/99	WIPO (with English Abstract) (corr. to USSN 09/485,699)		X
8	AQ	676 642	10/11/95	EUROPE (a copy has been received by the USPTO through the International Bureau, submitting corr. JP 7-280812 only)		
8	AR	7-280812	10/27/95	JAPAN (with English translation)	X	
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

8	AW	O. AL RAYYES, et al., Eur. J. Pharmacol., vol. 372, no. 3, 4 page, ENHANCEMENT OF LOW DENSITY LIPOPROTEIN CATABOLISM BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN CULTURED HepG2 CELLS, May 21, 1999 (submitting Abstract only of pages 311-318)
8	AX	A. ENDO, et al., Adv. Enzyme Regul., vol. 28, 1 page, BIOCHEMICAL ASPECT OF HMG CoA REDUCTASE INHIBITORS, 1989 (submitting Abstract only of pages 53-64)
	AY	
	AZ	

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.